286 related articles for article (PubMed ID: 9259093)
1. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
Brinkley WM; Torti FM
Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093
[TBL] [Abstract][Full Text] [Related]
2. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
4. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ
Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557
[TBL] [Abstract][Full Text] [Related]
5. Combined systemic therapy and radiotherapy for bladder cancer.
Rödel C; Weiss C; Sauer R
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():29-31. PubMed ID: 18167005
[No Abstract] [Full Text] [Related]
6. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M
Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Abi-Aad AS
Acta Urol Belg; 1996 May; 64(2):43-5. PubMed ID: 8701810
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
Pal SK; Ruel NH; Wilson TG; Yuh BE
Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
12. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
13. Novel gemcitabine-containing triplets in the management of urothelial cancer.
Hussain M; Vaishampayan U; Smith DC
Semin Oncol; 2002 Feb; 29(1 Suppl 3):20-4. PubMed ID: 11894004
[TBL] [Abstract][Full Text] [Related]
14. [Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Asadauskiene J; Aleknavicius E; Zelviene TP; Jankevicius F
Medicina (Kaunas); 2006; 42(10):781-7. PubMed ID: 17090976
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine doublets in advanced urothelial cancer.
Stadler WM
Semin Oncol; 2002 Feb; 29(1 Suppl 3):15-9. PubMed ID: 11894003
[TBL] [Abstract][Full Text] [Related]
16. Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup
Ann Acad Med Singap; 2015 Oct; 44(10):415-20. PubMed ID: 26763059
[TBL] [Abstract][Full Text] [Related]
17. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Roth BJ; Bajorin DF
J Urol; 1995 Mar; 153(3 Pt 2):894-900. PubMed ID: 7853569
[No Abstract] [Full Text] [Related]
18. New approaches to treatment of metastatic bladder cancer.
Edelman MJ
Curr Oncol Rep; 2000 Sep; 2(5):379-85. PubMed ID: 11122868
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
